

Woldesellassie M Bezabhe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3845885/publications.pdf>

Version: 2024-02-01

28
papers

731
citations

758635

12
h-index

580395

25
g-index

33
all docs

33
docs citations

33
times ranked

1145
citing authors

#	ARTICLE	IF	CITATIONS
1	Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 514-534.	1.1	7
2	Eight-Year Trends in Direct-Acting Oral Anticoagulant Dosing, Based on Age and Kidney Function, in Patients With Atrial Fibrillation. <i>Journal of Patient Safety</i> , 2022, 18, 337-341.	0.7	2
3	Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data. <i>Expert Review of Clinical Pharmacology</i> , 2022, , 1-7.	1.3	2
4	Oral Anticoagulant Treatment and the Risk of Dementia in Patients With Atrial Fibrillation: A Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023098.	1.6	18
5	Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 359-364.	1.3	2
6	Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing <i>Escherichia coli</i> between healthcare and community settings: a systematic review and meta-analysis. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, .	0.9	30
7	Improving Knowledge and Early Detection of Atrial Fibrillation through a Community-Based Opportunistic Screening Program: What's Your Beat?. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6860.	1.2	4
8	Risk of osteoporosis in patients with atrial fibrillation with and without oral anticoagulant therapy. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1003-1010.	1.3	2
9	The global prevalence and trend of human intestinal carriage of ESBL-producing <i>Escherichia coli</i> in the community. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 22-29.	1.3	110
10	Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13457.	1.7	11
11	COVID-19 in Ethiopia: a geospatial analysis of vulnerability to infection, case severity and death. <i>BMJ Open</i> , 2021, 11, e044606.	0.8	16
12	Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021, 12, 586370.	1.6	20
13	Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes. <i>BMC Infectious Diseases</i> , 2021, 21, 527.	1.3	9
14	Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13489.	1.7	11
15	Ten-year trends in prescribing of antiarrhythmic drugs in Australian primary care patients with atrial fibrillation. <i>Internal Medicine Journal</i> , 2021, 51, 1732-1735.	0.5	2
16	Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3568.	1.0	14
17	Quality use of medicines in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2020, 21, 216.	0.8	18
18	Medication Prescribing Quality in Australian Primary Care Patients with Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 783.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Development and Validation of an Atrial Fibrillation Knowledge Assessment Tool (AFKAT). International Journal of Environmental Research and Public Health, 2020, 17, 1721.	1.2	6
20	Factors associated with first-line antiretroviral treatment failure in adult HIV-positive patients: a case-control study from Ethiopia. BMC Infectious Diseases, 2019, 19, 537.	1.3	14
21	Applying the Capability, Opportunity, and Motivation Behaviour Model (COM-B) to Guide the Development of Interventions to Improve Early Detection of Atrial Fibrillation. Clinical Medicine Insights: Cardiology, 2019, 13, 117954681988513.	0.6	12
22	Effect of a Fucoidan Extract on Insulin Resistance and Cardiometabolic Markers in Obese, Nondiabetic Subjects: A Randomized, Controlled Trial. Journal of Alternative and Complementary Medicine, 2019, 25, 346-352.	2.1	14
23	Adherence to Antiretroviral Therapy and Virologic Failure. Medicine (United States), 2016, 95, e3361.	0.4	199
24	Antiretroviral adherence and treatment outcomes among adult Ethiopian patients. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1018-1022.	0.6	12
25	Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study From Ethiopia. Drug Safety, 2015, 38, 629-639.	1.4	20
26	Authors' Reply to Cotton and Nicol's Comment on "Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study from Ethiopia". Drug Safety, 2015, 38, 933-933.	1.4	0
27	Barriers and Facilitators of Adherence to Antiretroviral Drug Therapy and Retention in Care among Adult HIV-Positive Patients: A Qualitative Study from Ethiopia. PLoS ONE, 2014, 9, e97353.	1.1	151
28	Adherence to antiretroviral drug therapy in adult patients who are HIV-positive in Northwest Ethiopia: a study protocol. BMJ Open, 2013, 3, e003559.	0.8	11